National Institutes of Health to Grant Exclusive Patent License for Oral Treatment of Hemophilia

Summary

The National Institutes of Health is considering granting an exclusive patent license to ProGenetics, LLC, to practice inventions related to oral treatment of hemophilia, with potential worldwide territory and limited use to treating Hemophilia A and B and immunotolerization using oral delivery methods.